Medical Device Nonvisual Accessibility Act of 2025

HR5605 was introduced in the House on September 26, 2025, by Rep. Schakowsky (D-IL) and referred to the House Energy and Commerce Committee. It has 21 cosponsors — bipartisan but not leadership-heavy. The bill mandates that the FDA establish nonvisual accessibility standards (speech output, tactile controls, screen-reader compatibility) for medical devices with digital interfaces, particularly those used at home. It is pure regulatory mandate: it authorizes zero spending. No appropriation. No grants. No tax credits. The burden falls entirely on manufacturers to design compliant products.

The money trail is simple: this bill imposes compliance costs on medical device manufacturers. There is no government money going to anyone. Companies will spend R&D dollars to retrofit existing products or design new production lines. For large diversified companies like MDT ($79.57, near 52-week low of $78.91) and ABT ($91.35, also near 52-week low of $90.72), the cost is manageable — these companies have large cash flows and broad product lines. For pure-play smaller caps TNDM ($18.53) and DXCM ($57.83), compliance costs are a higher percentage of revenue but still not existential.

The real market data shows all four tickers in a 30-day slide: MDT -8.17%, ABT -11.03%, DXCM -7.91%, TNDM -3.34% over the past month. This broad weakness is driven by macro/sector forces (interest rates, reimbursement uncertainty) — not this bill, which is in early lap. The bill has no scheduled markups or hearings per the action history (single referral to committee in September 2025, no further actions). Legislative velocity is zero.

Structural winners and losers: The biggest relative loser is TNDM — smallest revenue base, most exposed to compliance cost as a % of revenue, and limited market-expansion upside because insulin pump adoption is constrained by clinical criteria, not vision status. DXCM is similar but larger, so less harmed. MDT and ABT have diversified revenue and can absorb costs, and may see modest upside if the mandate opens the diabetes/BP monitor/cardiac monitor market to visually impaired patients — a population of roughly 7 million in the US. This is a niche expansion, not a sector-wide shift.

Timeline: This bill must pass through the House Energy and Commerce Committee, then the full House, then the Senate (no companion bill exists), then be signed into law. The 119th Congress has until January 2027. With 21 cosponsors and no hearings yet, passage is uncertain in this session. Regulatory implementation (FDA rulemaking) would take 1-3 years post-enactment. No near-term market impact.